Vol. 5 No. 12 (2025)
Reimbursement Reviews

Dupilumab (Dupixent)

decorative image of the issue cover

Published December 17, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Dupilumab (Dupixent), 300 mg single-use prefilled syringe or pen administered by SC injection
  • Indication: For the treatment of adult patients with moderate-to-severe PN whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab can be used with or without topical corticosteroids.